Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Board Change

1 Feb 2023 07:00

RNS Number : 4956O
NetScientific PLC
01 February 2023
 

Strictly embargoed until: 07.00, 1 February 2023

NetScientific plc

("NetScientific" or the "Company")

Board Change

London, UK: NetScientific plc (AIM: NSCI), the investment and commercialisation group with an international portfolio of innovative life science, sustainability, and technology companies today announces that, further to the Company's previous announcement on 9 November 2022, John Clarkson has stepped down as Chairman of the Company, and resigned from the Board with immediate effect. 

Jonathan Robinson, Non-Executive Director of the Company will now become Interim Non-Executive Chairman while the Company completes its recruitment process to appoint a new Chairman.

Dr Ilian Iliev, Chief Executive Officer of the Company commented:

"John has been with NetScientific in various senior Board roles since December 2019. His excellent counsel, hard work, and professional oversight have contributed greatly to the Company's successful turnaround, placing the business on a path to growth. He was also instrumental as an architect of the turnaround strategy, and supported the executive team in its implementation. The Board wishes to thank John for his guidance and support and wishes him every success for the future. We also look forward to continuing to work with him in an advisory role both in the group and in various portfolio companies.

"Our search for a new Non-Executive Chairman is continuing well. The Nomination Committee has already received several applications from well qualified candidates, and interviews will be taking place shortly. We look forward to concluding the process soon and updating the market at the appropriate time. In the meantime, we are grateful to Jonathan Robinson, who is an experienced company director and will act as Interim Chairman until the search process is complete."

 

-Ends-

 

The person responsible for arranging the release of this announcement on behalf of the Company is Ilian Iliev, Chief Executive Officer of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAFFFDEEDEAA
Date   Source Headline
18th Jul 20187:00 amRNSWanda Technology Enhancements
26th Jun 20184:24 pmRNSGrant of Options to Directors
21st Jun 20181:33 pmRNSResult of AGM
6th Jun 20187:00 amRNSBob Englert Appointed CEO of Vortex Biosciences
4th Jun 20187:00 amRNSProAxsis Wins Innovative Business of Year in NI
1st Jun 20187:00 amRNSProAxsis Awarded Invest NI Grant
22nd May 20184:21 pmRNSNotice of AGM and Annual Report & Accounts
21st May 20187:00 amRNSWanda Announces Significant Data with Partner HRS
2nd May 20187:00 amRNSProAxsis to Present New Data at ATS 2018
18th Apr 20185:08 pmRNSDirectors Dealing Notification
16th Apr 20182:04 pmRNSResult of General Meeting
16th Apr 20187:25 amRNSVortex to Present 2 Posters at AACR
11th Apr 201811:39 amRNSResult of Placing
3rd Apr 20184:09 pmRNSPosting of Circular
29th Mar 20187:00 amRNSProposed Placing and Subscription
29th Mar 20187:00 amRNSFull Year Results
19th Mar 20187:00 amRNSWanda Expanding to Orthopedic Analytics
13th Mar 20187:00 amRNSVortex Announces Partnership with BioView
15th Feb 20187:00 amRNSProAxsis Reports First NEATstik Sale
9th Feb 20187:00 amRNSVortex Releases Publication in Nature Scientific
16th Jan 20187:00 amRNSNetScientific Portfolio Update
8th Jan 20187:00 amRNSProAxsis Achieves CE Mark for Plasmin Immunoassay
4th Jan 20187:00 amRNSGlycotestT Completes Diagnostic Evaluation
12th Dec 20177:00 amRNSWanda Awarded Two Patents
21st Nov 20177:00 amRNSProAxsis: Sales Update
7th Nov 20177:00 amRNSVortex Announces First Commercial VTX-1 Sale
2nd Nov 20177:00 amRNSGlycotest Adds Allowed Chinese Patent to Portfolio
1st Nov 201711:00 amRNSVortex Announces Liquid Biopsy Study in NPJ
30th Oct 20177:00 amRNSProAxsis Showcases ProteaseTag® Research at NACFC
27th Oct 20177:00 amRNSProAxsis Partnership - US National Jewish Health
25th Oct 20177:00 amRNSDirectorate Change
5th Oct 20177:00 amRNSGlycotest Granted Japanese Patent
2nd Oct 20177:00 amRNSWanda Awarded US Patent
28th Sep 20177:00 amRNS2017 Interim Results
14th Sep 20177:00 amRNSProAxsis appoints Diagenics Limited as Distributor
11th Sep 20177:00 amRNSProAxsis Signs Partnership: Biotechnology Company
7th Sep 20177:00 amRNSNotice of Interim Results
4th Sep 20177:00 amRNSProAxsis is awarded a European CE Mark
24th Jul 20177:00 amRNSProAxsis awarded a Significant Innovate UK Grant
10th Jul 201712:00 pmRNSPDS Announces Clinical Collaboration with Merck
7th Jul 20177:00 amRNSGlycotest Strengthens Intellectual Property Reach
26th Jun 20177:00 amRNSGlycotest Update
21st Jun 201712:00 pmRNSResult of AGM
16th Jun 201710:05 amRNSHoldings in Company
15th Jun 20172:52 pmRNSHoldings in Company
12th Jun 201712:02 pmRNSResults of General Meeting
12th Jun 201711:10 amRNSResult of Placing
26th May 20173:52 pmRNSNotice of AGM and Annual Report & Accounts
26th May 201712:49 pmRNSResults of Placing and Subscription
25th May 201711:51 amRNSProposed Placing and Subscription

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.